CN114010629A - 三麦芽酚铁的剂量方案 - Google Patents

三麦芽酚铁的剂量方案 Download PDF

Info

Publication number
CN114010629A
CN114010629A CN202111268204.XA CN202111268204A CN114010629A CN 114010629 A CN114010629 A CN 114010629A CN 202111268204 A CN202111268204 A CN 202111268204A CN 114010629 A CN114010629 A CN 114010629A
Authority
CN
China
Prior art keywords
iron
formulation
anemia
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111268204.XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·施魏格尔
卡尔·安德鲁·斯特瑞特
朱利安·大卫·豪厄尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201400171A external-priority patent/GB201400171D0/en
Priority claimed from GB201418708A external-priority patent/GB201418708D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CN114010629A publication Critical patent/CN114010629A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202111268204.XA 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案 Pending CN114010629A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201400171A GB201400171D0 (en) 2014-01-06 2014-01-06 Dosage regimen
GB1400171.3 2014-01-06
GB1418708.2 2014-10-21
GB201418708A GB201418708D0 (en) 2014-10-21 2014-10-21 Dosage regimen
CN201580005412.7A CN106413706A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580005412.7A Division CN106413706A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Publications (1)

Publication Number Publication Date
CN114010629A true CN114010629A (zh) 2022-02-08

Family

ID=52432872

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111268204.XA Pending CN114010629A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案
CN201580005412.7A Pending CN106413706A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580005412.7A Pending CN106413706A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Country Status (12)

Country Link
US (1) US10179120B2 (https=)
EP (1) EP3091974B1 (https=)
JP (2) JP6556753B2 (https=)
KR (1) KR102351422B1 (https=)
CN (2) CN114010629A (https=)
AU (1) AU2015204192B2 (https=)
BR (1) BR112016015766A2 (https=)
CA (1) CA2934836C (https=)
ES (1) ES2785391T3 (https=)
IL (1) IL246613B (https=)
SI (1) SI3091974T1 (https=)
WO (1) WO2015101971A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179120B2 (en) 2014-01-06 2019-01-15 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
GB201418710D0 (en) * 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
KR102341615B1 (ko) 2016-03-31 2021-12-21 실드 티엑스 (유케이) 리미티드 암 및 종양의 치료 또는 예방에서 사용하기 위한 제2철 말톨 조성물
JP7033546B2 (ja) 2016-03-31 2022-03-10 シールド ティーエックス （ユーケー） リミテッド 元素鉄からマルトール第二鉄組成物を生成するための方法
US11267836B2 (en) 2016-03-31 2022-03-08 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
US10508094B2 (en) 2016-03-31 2019-12-17 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ferrous hydroxides
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
WO2026017897A1 (en) 2024-07-18 2026-01-22 Malian Biologicals Gmbh Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases
GB202414014D0 (en) 2024-09-24 2024-11-06 Shield Tx Uk Ltd Use of ferric trimaltol in treating of preventing iron deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
US20080234226A1 (en) * 2005-08-25 2008-09-25 Vifor (International) Ag Use Of Iron(III) Complex Compounds For The Preparation Of A Medicament For Oral Treatment Of Iron Deficiency States In Patients With Chronic Inflammatory Bowel Disease
CN103443091A (zh) * 2011-01-27 2013-12-11 阿文斯若皮帝克斯控股股份公司 方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150213B (it) 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
RO113611B1 (ro) 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
EP0833627B1 (en) 1995-06-10 2004-08-18 Vitra Pharmaceuticals Ltd. Iron compounds, compositions, methods of making the same and uses thereof
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
AU2001287850A1 (en) 2000-09-19 2002-04-02 Vitra Pharmaceuticals Limited Iron compositions
US20050118291A1 (en) 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
MX2007013708A (es) 2005-05-03 2008-01-28 Innozen Inc Pelicula comestible para suministro transmucosa de complementos nutricionales.
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
JP5856725B2 (ja) 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
US10179120B2 (en) 2014-01-06 2019-01-15 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
US20080234226A1 (en) * 2005-08-25 2008-09-25 Vifor (International) Ag Use Of Iron(III) Complex Compounds For The Preparation Of A Medicament For Oral Treatment Of Iron Deficiency States In Patients With Chronic Inflammatory Bowel Disease
CN103443091A (zh) * 2011-01-27 2013-12-11 阿文斯若皮帝克斯控股股份公司 方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. S. J. HARVEY: "Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron", ALIMENT PHARMACOL THER, no. 12, 31 December 1998 (1998-12-31), pages 846 *

Also Published As

Publication number Publication date
JP6556753B2 (ja) 2019-08-07
KR20160105499A (ko) 2016-09-06
AU2015204192A1 (en) 2016-07-07
US10179120B2 (en) 2019-01-15
ES2785391T3 (es) 2020-10-06
EP3091974B1 (en) 2020-04-01
SI3091974T1 (sl) 2020-08-31
JP2017501235A (ja) 2017-01-12
WO2015101971A1 (en) 2015-07-09
IL246613A0 (en) 2016-08-31
AU2015204192B2 (en) 2020-03-26
CN106413706A (zh) 2017-02-15
CA2934836C (en) 2022-03-22
KR102351422B1 (ko) 2022-01-13
EP3091974A1 (en) 2016-11-16
US20160324822A1 (en) 2016-11-10
JP2019131592A (ja) 2019-08-08
BR112016015766A2 (pt) 2017-08-08
CA2934836A1 (en) 2015-07-09
IL246613B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CA2934836C (en) Dosage regimen of ferric trimaltol
KR102150135B1 (ko) 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
US20140221434A1 (en) Altering pharmacokinetics of pirfenidone therapy
JP2021073230A (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
CA2965096C (en) Dosage regiment of ferric maltol
US20240148730A1 (en) Method for treating cancer patients with severe renal impairment
HK40065667A (zh) 三麦芽酚铁的剂量方案
US12251400B2 (en) Liquid concentrates of calcium and magnesium
KR100631873B1 (ko) 생체이용율이 증진된 알렌드론산 제제
TW202547454A (zh) 治療前的尿白蛋白濃度在特定範圍之慢性腎臟病的治療用醫藥組成物
Fernández Martínez et al. Effects of dietary factors on levodopa pharmacokinetics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065667

Country of ref document: HK